A.S. v. SmithKline Beecham Corp.A.S. v. SmithKline Beecham Corp.
OPINION
A.S. and Sallee Miller (“Plaintiffs”) filed suit in Pennsylvania state court against GlaxoSmithKline LLC (“GSK”) claiming that its drug, Paxil, caused birth defects. GSK removed the case to the United States District Court for the Eastern District of Pennsylvania. The District Court
1
remanded the case, finding that GSK was a citizen of Pennsylvania and therefore ineligible to remove the case. After remand, our Court decided
Johnson v. SmithKline Beecham Corp.,
I
On September 30, 2011, A.S., who suffers from a congenital birth defect, and his mother, Sallee Miller, who ingested Paxil while pregnant, sued GSK in the Philadelphia County Court of Common Pleas. App. 82-84. The complaint alleged that all parties were citizens of Pennsylvania. App. 53, 84-85. GSK removed the case within thirty days of receipt of the complaint based upon diversity. On Plaintiffs’ motion, the case was consolidated with a number of other Paxil cases before a district court judge who had previously held that GSK was a citizen of Pennsylvania. Consistent with that holding, the District Court remanded’ this case along with the other consolidated cases to state court, holding that GSK was a citizen of Pennsylvania and could not remove a case from Pennsylvania state court to federal court.
Patton ex rel. Daniels-Patton v. Smith-Kline Beecham Corp.,
CIV.A. 11-5965,
On June 7, 2013, this Court issued
Johnson,
which held that GSK was a citizen of Delaware.
Johnson,
Less than thirty days after the
Johnson
decision, GSK filed a second notice of removal in this case and in eight other cases with the same procedural posture. App. 29-48. The various plaintiffs filed motions to remand, arguing that the removal was untimely. App. 319. These motions yielded inconsistent opinions. The first case holding that removal was proper was
Gud-deck v. SmithKline Beecham Corp.,
After the rulings in
Guddeck
and this case, more judges in the Eastern District weighed in. One denied remand in two of the nine cases presenting the same issue, relying on the reasoning in
Guddeck. See M.N. v. SmithKline Beecham Corp.,
No. 2:13-cv-3695-RB, Dkt. 17 (E.D.Pa. Aug. 7, 2013);
I.C. v. SmithKline Beecham Corp.,
No. 2:13-cv-3681-RB, Dkt. 22 (E.D.Pa. Aug. 9, 2013). Two judges disagreed and granted the motions to remand.
See Cammarota ex rel. Hallock v. SmithKline Beecham Corp.,
CIV.A. 13-3677,
II
This Court has jurisdiction to address not only the certified question but “any issue fairly included within the certified order,”
Johnson,
III
We will first review the removal provisions at issue. Under
Plaintiffs contend that GSK’s most recent removal did not comply with the time limits for removal set forth in
The notice of removal of a civil action or proceeding shall be filed within thirty days after the receipt by the defendant, through service or otherwise, of a copy of the initial pleading setting forth the claim for relief upon which such action or proceeding is based, or within thirty days after the service of summons upon the defendant if such initial pleading has then been filed in court and is not required to be served on the defendant, whichever period is shorter.
If the case stated by the initial pleading is not removable, a notice of removal may be filed within thirty days after receipt by the defendant, through service or otherwise, of a copy of an amended pleading, motion, order or other paper from which it may first be ascertained that the case is one which is or has become removable, except that a case may not be removed on the basis of [diversity jurisdiction] more than 1 year after commencement of the action.
Id.
Plaintiffs also claim that the order denying remand violated
For the reasons set forth herein, GSK’s re-removal is prohibited by
A
GSK argues that
B
The second paragraph does not relieve GSK of the first paragraph’s bar. It is an exception to the thirty-day time limit in the first paragraph. This paragraph sets a separate thirty-day time limit that applies when: (1) “the case stated by the initial pleading is not removable” and (2) the defendant receives “an amended pleading, motion, order or other paper” (3) from which “it may first be ascertained that the
1
Even assuming the case stated by the initial pleading was not removable, GSK also cannot rely on the second paragraph because there was no “ámended pleading, motion, order or other paper” to trigger its thirty-day time limit. In general, the terms “amended pleading, motion, order or other paper” only “address[ ] developments within a case” and, therefore, court decisions in different cases do not count as an “order.”
Dahl v. R.J. Reynolds Tobacco Co.,
Our Court has recognized a narrow exception to the general rule that orders issued in other cases do not qualify as a
The Red Cross re-removed the case within thirty days of
S.G.
and plaintiffs moved to remand, arguing, among other things, that
S.G.
was not an “order” under
Johnson
is no
S.G. Johnson
rejected the reasoning that led to the remand of this case, as it held that GSK is a Delaware citizen, but it did not include the explicit authorization to remove other pending cases. Put simply,
“Johnson ...
merely affirmed” an “[order denying] remand in the case before it.”
Powell,
Our binding precedent in
Doe
made clear, however, that its ruling was narrow and meant to apply in “unique circumstances,” namely compliance with a higher court’s holding that explicitly authorized a particular party to remove all of its pending eases to federal court.
Doe,
Moreover, if a party in a pending case could re-remove each time it received a favorable ruling in another case, re-removal could be a means to disrupt the proceedings in the pending case.
Wilson v. Intercollegiate (Big Ten) Conference Athletic Ass’n,
Because
Johnson
did not explicitly direct removal of all cases involving GSK, but only affirmed the order denying remand of the case, it is not an “order” that triggers a new thirty-day time period to remove Plaintiffs’ case. For this additional reason, the second paragraph of
2
GSK is also barred from removal based upon the second paragraph’s one-year limitation, which prohibits removal of diversity cases more than one year after the case commences. Here, the case commenced on September 30, 2011, and the notice of removal at issue was filed on June 26, 2013, more than a year and a half later. App. 18-19.
This one-year time limit is procedural, not jurisdictional.
Ariel Land Owners, Inc. v. Dring,
Equitable tolling is not warranted in this case. Cases involving equitable tolling of the one-year time limit often focus on intentional misconduct by the plaintiff.
See e.g., Tedford,
While the contours of equitable tolling vary from context to context, this Court and the Supreme Court have held that equitable tolling may be appropriate if a litigant can demonstrate “(1) that he has been pursuing his rights diligently, and (2) that some extraordinary circumstance stood in his way.”
Pace v. DiGuglielmo,
GSK argues that “extraordinary circumstances thwarted [its] initial removal.” GSK Br. 36. According to GSK, the “extraordinary circumstances” were: (1) that the remand proceedings were consolidated before a judge who had previously held that GSK was a citizen of Pennsylvania and therefore was likely to find that remand was proper; and (2) that the District Court erroneously remanded the case.
Neither is an “extraordinary circumstance.” Section 137 of Title 28 provides that “[t]he business of a court having more than one judge shall be divided among the judges as provided by the rules and orders of the court.” This statute “vests the district court with broad discretion in assigning court business to individual judges.”
United States v. Diaz,
Furthermore, although the original remand decision was wrong, an erroneous remand is not an “extraordinary circumstance.” In fact,
For these reasons, GSK is not entitled to equitable tolling.
C
GSK’s final argument is that its second notice of removal should “relate back” to the first notice of removal. To assess this argument, we must first identify the source of a court’s authority to relate back in this context. GSK relies on
GSK argues that this case “warrants the exercise of those equitable powers.” GSK Br. 30. The reasons GSK gives in favor of equitable relation back simply rehash its arguments for equitable tolling and for the same reasons, they fail. Neither the fact that a particular judge was assigned to the case nor the error in remanding the case provide a basis for equitable relief.
An additional reason dictates that the second notice of removal does not relate back to the first notice of removal. By the time GSK filed its second notice of removal, a final order remanding the action had been filed and the case was sent to the state court. As a result, there was nothing pending in the federal court to which the second notice could relate. This distinguishes the present case with those that GSK cites as supporting relation back, such as
USX Corp. v. Adriatic Insurance Co.,
There is a critical difference between this case and
USX.
In this case, GSK’s first notice of removal was not pending but was disposed of by a final order remanding the case to state court.
See In re FMC Corp. Packaging Sys. Div.,
Recognizing this obvious distinction, GSK argues that the initial notice does not need to be pending, but rather that only the underlying case must be pending. For this proposition, GSK cites to cases where courts allowed an amended complaint to relate back to a timely, yet dismissed complaint. These cases allowed relation back only when the complaint was dismissed without prejudice — i.e., by a non-final order.
7
See Brennan v. Kulick,
Moreover, once an order remanding a case is mailed to the state court, the district court loses jurisdiction and thus lacks the authority to allow the amendment of the notice of removal. In
Hunt,
a district court remanded a case to .state court, thereby losing jurisdiction over the case.
For all of these reasons, GSK’s second notice of removal cannot relate back to the first notice of removal. 8
IV
Because GSK’s second removal was untimely under
Notes
. Several district court judges entered orders in this case. We will refer to the judges collectively as the "District Court."
.
Except as otherwise expressly provided by Act of Congress, any civil action brought in a State court of which the district courts of the United States have original jurisdiction, may be removed by the defendant or the defendants, to the district court of the United States for the district and division embracing the place where such action is pending.
. Because this case was commenced in 2011, all citations to
.
See Brown v. Jevic,
. This conclusion is consistent with our precedent that removal statutes are to be strictly construed against removal.
See, e.g., Abels v. State Farm Fire & Cas. Co.,
. The current version of
. The one case GSK cites that involved a dismissal with prejudice does not warrant a different view. In
Donnelly v. Yellow Freight Sys., Inc.,
. Plaintiffs also contend that